Figure 8.

Tolerability profile of selected ASOs in the CNS of wt mice and rats. (A and B) Non-transgenic mice (n = 4/group) were administered 300 µg of A1, A25, A30 or PBS by ICV injection and were monitored for tolerability for 8 weeks post-treatment. ASO treatment in non-transgenic mice did not alter (A) body weight or (B) striatal or cortical Aif1 mRNA levels. (C–G) Repeated IT dosing in rats every 2 weeks for 8 weeks did not alter (D) body mass, (E) hindlimb grip-strength, (F) time immobile in the open-field or (G) spinal cord mRNA levels of Aif1, Gfap or Mpeg1. Error bars are in±SEM.